MATT FRANCOM: Open Payments
NPI 1598910101 · WEST POINT, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$300 in 18 payments from 12 companies in 2025. Trend: 2023 $195 · 2024 $349 · 2025 $300
Food & beverage: $300
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 2 | $39 |
| Lilly USA, LLC | 2 | $39 |
| Corcept Therapeutics | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Almirall LLC | 1 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Organon LLC | 3 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
| ABBVIE INC. | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: COSENTYX, Korlym, REXULTI, Seysara, CAPLYTA, TALTZ, Sotyktu, VTAMA.
Industry payments across UT — which companies pay providers there.
